Impact of HIV Infection on Total Body Composition in Treatment-Naive Men Evaluated by Dual-Energy X-ray Absorptiometry Comparison of 90 Untreated HIV-Infected Men to 241 Controls

Journal of Clinical Densitometry

Volumn 10, Issue 4, 2007, Pages 376-380

  Delpierre, C ^a,b,c   Bonnet, E ^a   Marion Latard, F ^d   Aquilina, C ^e   Obadia, M ^a   Marchou, B ^a   Massip, P ^a   Perret, B ^a   Bernard, J ^d  

^a CHU PURPAN   (France)

^b INSERM   (France)

^c IFR126   (France)

^d CHU RANGUEIL   (France)

^e Serv Univ Psychiat l'Enfant l'A   (France)

Author keywords

body composition; Bone mineral density; fat mass ratio; HIV; untreated men

Indexed keywords

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; CATABOLISM; COMORBIDITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 35748957765     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2007.07.006     Document Type: Article

References (30)

1. Bonnet E., Delpierre C., Sommet A., et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men. J Clin Densitom 8 (2005) 287-292
2. Cavalcanti R., Cheung A., Raboud J., and Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. J Clin Densitom 8 (2005) 293-297
3. Weinroth S., Parenti D., and Simon G. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 4 (1995) 76-94
4. Cianfrocca M., and Von Roenn J. Wasting and cachexia in patients with HIV. AIDS Patient Care STDs 11 (1997) 259-267
5. Carr A., Samaras K., and Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 (1998) 51-58
6. Miller K., Jones E., Yanovski J., Shankar R., Feuerstein I., and Falloon J. Visceral abdominal fat accumulation associated with use of indinavir. Lancet 351 (1998) 871-875
7. Saves M., Raffi F., and Capeau J. Antiproteases cohorte (APROCO) study group: factors related to lipodystrophy and metabolic alterations in patients with human immuno-deficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34 (2002) 1396-1405
8. Mallal S., John M., Moore C., James I., and McKinnon E. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients receiving long-term nucleoside analogue therapy. AIDS 14 (2000) 1309-1316
9. Carr A., Miller J., Law M., and Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14 (2000) 25-32
10. Saint Marc T., Partisani M., and Poizot-Martin I. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy. AIDS 13 (1999) 1659-1667
11. Garcia Aparicio A., Munoz Fernandez S., Gonzalez J., et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 6 (2005) 1-3
12. Amiel C., Ostertag A., Slama L., et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19 (2004) 402-409
13. Bruera D., Luna N., David D., Bergoglio L., and Zamudio J. Decreased bone mineral density in HIV-infected patients is dependent of antiretroviral therapy. AIDS 17 (2003) 1917-1923
14. Fausto A., Bongiovanni M., Cicconi P., et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone (2005)
15. Thomas J., and Doherty S. HIV infection-a risk factor for osteoporosis. J Acquir Immune Defic Syndr 33 (2003) 281-291
16. Miller J., Carr A., and Smith D. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 14 (2000) 2406-2407
17. Martinez E., Mocroft A., and Garcia-Viejo M. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357 (2001) 592-598
18. Madge S., Kinloch-de-Loes S., Mercey D., Johnson M., and Weller I. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 13 (1999) 735-737
19. Mazess R., Barden H., Drinka P., Bauwens S., Orwoll E., and Bell N. Influence of age and body weight on spine and femur bone mineral density in US white men. J Bone Miner Res 5 (1990) 645-652
20. Charles M., Basdevant A., and Eschwege E. Prevalence of obesity in France: the situation established from the OBEPI study. Ann Endocrinol 63 (2002) 154-158
21. Karlsson M., Gardsell P., Johnell O., Nilsson B., Akesson K., and Obrant K. Bone mineral normative data in Malmo, Sweden. Comparison with reference data and hip fracture incidence in other ethnic groups. Acta Orthop Scand 64 (1993) 168-172
22. Jain R., and Lenhard J. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 277 (2002) 247-250
23. Seminari E., Castagna A., Soldarini A., et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 6 (2005) 145-150
24. Madeddu G., Spanu A., Solinas P., et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48 (2004) 39-48
25. Das S., Shahmanesh M., Stolinski M., et al. In treatment naive and antiretroviral treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL, and LDL apolipoprotein B-100. Diabetologia 49 (2006) 538-542
26. Aukrust P., Haug C., Ueland T., et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84 (1999) 145-150
27. Hansen A., Lindegaard B., Obel N., Andersen O., Nielsen H., and Gerstoft J. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med 7 (2006) 38-45
28. Lewis W., Kohler J., Hosseini S., et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 20 (2006) 675-684
29. Gerschenson M., Shiramizu B., LiButti D., and Shikuma C. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther 10 (2005) M83-M89
30. Jones S., Qazi N., Morelese J., et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 40 (2005) 565-572